SRSF2 and leukemia: In both univariate and multivariable analysis, leukemia-free survival was adversely affected by SRSF2 mutations (HR 4.7, 95% CI 1.3–16.9), very high-risk karyotype (HR 7.9, 95% CI 1.9–32.1), and circulating blasts ≥2% (HR 3.9, 95% CI 1.4–11.0).